Abcam, ab257590, Human PLCG1 (Phospholipase C gamma 1/PLC-gamma-1) knockout HEK-293T cell lysate

Size: 1Kit
PLCG1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 267 bp deletion in exon1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 267 bp deletion in exon1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PLCG1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Phospholipase C gamma 1 (PLC-gamma-1) also known as PLCG1 or PLC-gamma plays an important role in cellular signaling. This enzyme has a molecular mass of approximately 150 kDa. It is found in multiple cell types but is highly expressed in the brain and immune cells. PLC-gamma-1 is involved in the hydrolysis of phosphatidylinositol 45-bisphosphate (PIP2) to generate inositol 145-trisphosphate (IP3) and diacylglycerol (DAG) leading to downstream signaling events that control various cellular processes.
Biological function summary
PLC-gamma-1 is integral in signal transduction and is an important player in the immune response. The protein does not function as part of a large multi-protein complex but interacts transiently with other signaling molecules. It acts downstream of growth factor receptors and immunoreceptors by mediating calcium release and activation of protein kinase C influencing cell proliferation migration and differentiation. Its expression pattern suggests a critical role in the nervous and immune systems affecting learning memory and immune defense.
Pathways
PLC-gamma-1 is an important component in both the phospholipase C and PLC-gamma pathways. These pathways include important interactions with proteins such as the receptor tyrosine kinases and Src family kinases. In these pathways PLC-gamma-1 modulates signals that guide cellular responses to external stimuli affecting processes like growth signaling and T-cell receptor activation which is vital in adaptive immunity.
PLC-gamma-1 has significant connections to cancer and immune deficiencies. Abnormal PLC-gamma-1 activity is observed in certain cancers such as breast cancer where it influences tumor growth and metastasis. Its dysregulation in immune cells leads to disorders like autoimmune diseases by impacting proteins such as LAT and SLP-76 which are important in T-cell signaling. Understanding PLC-gamma-1’s regulatory mechanisms helps in developing targeted therapies for these conditions.